Comparative Pharmacology
Head-to-head clinical analysis: POTASSIUM IODIDE versus THYRO BLOCK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POTASSIUM IODIDE versus THYRO BLOCK.
POTASSIUM IODIDE vs THYRO-BLOCK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium iodide suppresses thyroid hormone synthesis and release via the Wolff-Chaikoff effect, inhibiting iodide organification and reducing vascularity of the thyroid gland.
THYRO-BLOCK (potassium iodide) inhibits thyroid hormone synthesis and release by blocking the oxidation of iodide to iodine, thereby preventing the incorporation of iodine into thyroglobulin. It also reduces the vascularity of the thyroid gland.
Oral: 300 mg (0.3 mL of saturated solution) three times daily for thyroid protection in radiation exposure; for hyperthyroidism preoperative: 60-250 mg (0.06-0.25 mL) three times daily.
Oral, 120 mg every 12 hours (total daily dose 240 mg) starting 24 hours before exposure to radioactive iodine and continuing for 5–10 days as directed.
None Documented
None Documented
Clinical Note
moderateWarfarin + Potassium Iodide
"Warfarin may decrease the anticoagulant activities of Potassium Iodide."
Clinical Note
moderatePhenprocoumon + Potassium Iodide
"Phenprocoumon may decrease the anticoagulant activities of Potassium Iodide."
Clinical Note
moderatePhenindione + Potassium Iodide
"Phenindione may decrease the anticoagulant activities of Potassium Iodide."
Clinical Note
moderateAcenocoumarol + Potassium Iodide
Terminal half-life in euthyroid individuals is approximately 13 days (range 10–15 days). In hyperthyroidism, half-life may be shortened to 5–6 days due to increased thyroid clearance; in hypothyroidism, half-life may be prolonged up to 40 days.
Terminal elimination half-life is approximately 36 hours (range 24-48 hours) in euthyroid patients; prolonged in hyperthyroid patients due to increased thyroid hormone binding and reduced clearance.
Renal: >90% of absorbed iodide is excreted in urine; fecal elimination is negligible (<2%).
Primarily renal excretion of unchanged drug (80-90% of absorbed dose) via glomerular filtration; minimal biliary/fecal elimination (<5%).
Category C
Category C
Antithyroid Agent
Antithyroid Agent
"Acenocoumarol may decrease the anticoagulant activities of Potassium Iodide."